A new instrument for predicting survival of patients with cerebral metastases from breast cancer developed in a homogeneously treated cohort
Abstract
Background: Previous survival scores for breast cancer patients with cerebral metastases were developed in cohorts receiving heterogeneous treatments, which could have introduced selection biases. A new instrument (WBRT-30-BC) was created from 170 patients receiving whole-brain radiotherapy (WBRT) alone with 30 Gy in 10 fractions.
Methods: Characteristics showing significant (p<0.05) associations with OS on univariate analysis or almost significant (p<0.055) associations on multivariate analysis were used for the WBRT-30-BC. For each characteristic, 6-month OS rates were divided by 10. These scoring points were added for each patient (patient scores). The WBRT-30-BC was compared to the diagnosis-specific graded prognostic assessment (DS-GPA) classification and Rades-Score for breast cancer regarding positive predictive values (PPVs) to identify patients dying within 6 months and patients surviving at least 6 months following WBRT.
Results: On univariate analyses, better OS was significantly associated with KPS >70% (p<0.001) and absence of extra-cerebral metastases (p=0.001). On multivariate analysis, KPS was significant (p<0.001); time between breast cancer diagnosis and WBRT was almost significant (p=0.053). Four predictive groups were designed: 7-9, 10-12, 13-15 and 16 points. Six-month OS rates were 8%, 41%, 68% and 100% (p<0.001). PPVs to identify patients dying within 6 months were 92% (WBRT-30-BC), 84% (DS-GPA) and 92% (Rades-Score). PPVs to identify patients surviving for at least 6 months were 100% (WBRT-30-BC), 74% (DS-GPA) and 68% (Rades-Score).
Conclusions: The WBRT-30-BC appeared very accurate in predicting death ≤6 months and survival ≥6 months of breast cancer patients receiving WBRT. It was superior to previous instruments in predicting survival ≥6 months.
Downloads
Published
How to Cite
Issue
Section
License
License to Publish
Please read the terms of this agreement, print, initial page 1, sign page 3, scan and send the document as one file attached to an e-mail to gsersa@onko-i.si